Vaccine Stocks Gained in Morning Trading.
Novavax stock rebounded nearly 12% after Covid-19 vaccines launch in U.K.
The Novavax vaccine is a protein-based vaccine administered as two shots given three weeks apart.
"With U.K. data showing that people infected with both Covid-19 and the flu are more than five times as likely to die compared with someone with no infection, it is more important than ever to consider any vaccine offered to you by the National Health Service," Novavax CEO Stanley Erck said in the news release.
"We continue to believe in the importance of a diversified national vaccine portfolio to reduce winter pressures on the health service," Erck added.
Comments